The need to consider the wider agenda in systematic reviews and meta-analyses: breadth, timing, and depth of the evidence.
Ioannidis
John P A
JP
Department of Hygiene and Epidemiology, University of Ioannina School of Medicine, Ioannina, Greece. jioannid@cc.uoi.gr
Karassa
Fotini B
FB
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002986:Clinical Trials as Topic; D019317:Evidence-Based Medicine; D006801:Humans; D015201:Meta-Analysis as Topic; D012196:Review Literature as Topic; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068258:Bevacizumab